(Q52931065)

9 May 2018

title

First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. (English)

1 reference

9 May 2018

author

Karsten Lunze

1

1 reference

9 May 2018

Felix Berger

10

1 reference

9 May 2018

author name string

N Gilbert

2

1 reference

9 May 2018

S Mebus

3

1 reference

9 May 2018

O Miera

4

1 reference

9 May 2018

W Fehske

5

1 reference

9 May 2018

F Uhlemann

6

1 reference

9 May 2018

E G Mühler

7

1 reference

9 May 2018

P Ewert

8

1 reference

9 May 2018

P E Lange

9

1 reference

9 May 2018

I Schulze-Neick

11

1 reference

9 May 2018

publication date

1 September 2006

1 reference

9 May 2018

European Journal of Clinical Investigation

published in

1 reference

9 May 2018

volume

36 Suppl 3

1 reference

9 May 2018

page(s)

32-38

1 reference

9 May 2018

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Successful transplantation of organs from a donor who died from acute cocaine intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

The registry of the international society for heart and lung transplantation: nineteenth official report-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Effects of long-term bosentan in children with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01692.X

10.1111/J.1365-2362.2006.01692.X

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

16919008

1 reference

9 May 2018